29. Breast Care (Basel). 2018 Jul;13(3):216-219. doi: 10.1159/000490746. Epub 2018Jun 20.PARP Inhibitors in Breast Cancer: Why, How, and When?Paradiso A(1), Andreopoulou E(2), Conte P(3)(4), Eniu A(5), Saghatchian M(6).Author information: (1)Experimental Medical Oncology, Istituto Tumori G. Paolo II, IRCCS, Bari,Italy.(2)Weill Cornell Breast Center, Division of Hematology and Medical Oncology,Weill Cornell Medicine, New York, NY, USA.(3)Department of Surgery, Oncology and Gastroenterology, University of Padova,Padua, Italy.(4)Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua,Italy.(5)Department of Breast Tumors, Cancer Institute 'Ion Chiricuta', Cluj-Napoca,Romania.(6)Breast Cancer Unit, American Hospital of Paris, Neuilly-sur-Seine, France.DOI: 10.1159/000490746 PMCID: PMC6062717 [Available on 2019-07-01]PMID: 30069183 